Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Details)

v3.19.3.a.u2
Accrued Expenses (Details) - USD ($)
Dec. 31, 2019
Mar. 31, 2019
Payables and Accruals [Abstract]    
Accrued expenses for AV-101, PH94B, and PH10 clinical trial, development and related expenses $ 876,600 $ 1,067,600
Accrued compensation 0 439,200
Accrued professional services 66,800 172,100
All other 7,900 6,700
Total $ 951,300 $ 1,685,600